Current disease status-First occurrence of the leukemia Page 2 Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the leukemia Posts on Medivizor

Looking for young patients with B-cell acute lymphoblastic leukemia to test a new T-cell therapy

Posted by on Apr 22, 2019 in Leukemia | 0 comments

In a nutshell This phase 2 trial is evaluating the effectiveness of huCART19 cell therapy in young patients with high-risk B-cell acute lymphoblastic leukemia (ALL). The main outcome to be measured will be survival without a treatment-related complication. This study is being conducted in Philadelphia, Pennsylvania, United States. The details Acute...

Read More

Looking for elderly patients with chronic lymphocytic leukemia to test a treatment combination

Posted by on Mar 16, 2019 in Leukemia | 0 comments

In a nutshell This trial is examining the effectiveness of ibrutinib and obinutuzumab with or without venetoclax in the treatment of older patients with chronic lymphocytic leukemia (CLL). The main outcome to be measured will be survival without cancer worsening. This trial is recruiting in the United States. The details Patients with CLL are often...

Read More

Long-term effectiveness of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia

Posted by on Mar 16, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of tyrosine kinase inhibitors for chronic-phase chronic myeloid leukemia. This study concluded that the outcomes for these patients are satisfactory and reliable. Some background Patients with chronic phase chronic myeloid leukemia (CP-CML) generally have mild...

Read More

Searching for patients with newly-diagnosed AML to try this new treatment option

Posted by on Mar 15, 2019 in Leukemia | 0 comments

In a nutshell This Phase 3 study is evaluating the safety and effectiveness of midostaurin (Rydapt) combined with chemotherapy for patients with newly-diagnosed acute myeloid leukemia (AML). The main outcome to be measured will be event-free survival at 5 years. The details Previous studies have shown that midostaurin combined with chemotherapy is...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive chronic lymphocytic leukemia

Posted by on Feb 28, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive chronic lymphocytic leukemia (CLL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in relapsed/unresponsive CLL.  Some background...

Read More

Treatment of childhood ALL with therapy to the spinal area

Posted by on Feb 28, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the use of medication delivered to the spinal area (intrathecal) in patients with acute lymphoblastic leukemia (ALL). Researchers showed that this may be used instead of radiation to the head in these patients, with similar outcomes. Some background Acute lymphoblastic leukemia is a cancer of the immune system that...

Read More

Evaluating nilotinib with chemotherapy for acute lymphoblastic leukemia with abnormal genes

Posted by on Jan 31, 2019 in Leukemia | 0 comments

In a nutshell This study wanted to assess the safety and effectiveness of nilotinib (Tasigna) in the treatment of acute lymphoblastic leukemia (ALL) with abnormal genes. Researchers found that nilotinib was safe and effective in these patients when combined with chemotherapy. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the immune...

Read More

Evaluating long-term Intensive chemotherapy combined with ponatinib for ALL treatment

Posted by on Dec 29, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to assess the long-term safety and effectiveness of adding ponatinib (Iclusig) to intensive chemotherapy in the treatment of acute lymphoblastic leukemia. The study found that this treatment is effective on the long-term for these patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone...

Read More

Inotuzumab ozogamicin for children with unresponsive acute lymphoblastic leukemia

Posted by on Dec 21, 2018 in Leukemia | 0 comments

In a nutshell This study wanted to assess the safety and effectiveness of inotuzumab ozogamicin (InO; Besponsa) for the treatment of children with unresponsive acute lymphoblastic leukemia (ALL). Researchers found that InO was safe and effective in this group of patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone...

Read More